The muscle problem with GLP-1s finally has trial data behind it
By the DoseRoutine Editorial Team · · · How we review content
Up to 40% of the weight lost on GLP-1 therapy can come from lean mass, not fat. Two Phase 2 programs now show that this is partly fixable with drugs: the BELIEVE trial combined semaglutide with bimagrumab (an activin-receptor blocker) and produced greater total weight loss while preserving lean mass, and Regeneron's COURAGE trial combining semaglutide with trevogrumab (anti-myostatin) prevented roughly half of the semaglutide-induced lean-mass loss while increasing fat loss.
- BELIEVE (published in Nature Medicine, March 2026): semaglutide plus bimagrumab produced more weight loss with lean mass preserved, so a much larger share of the loss was fat.
- COURAGE (26-week Phase 2 data): semaglutide plus trevogrumab prevented about half the lean-mass loss and increased fat-mass loss.
- Both are investigational combinations — neither is approved, and neither is available outside trials.
- Nothing here replaces the two interventions that already work: adequate protein and progressive resistance training.
- If you are on a GLP-1, scale weight is the wrong single metric. Track fat and lean mass separately.
Why lean mass falls at all
Any large energy deficit costs some lean tissue — that is normal physiology, and part of the 'lean mass' in a DXA scan is water, glycogen and connective tissue rather than contractile muscle. What makes incretin therapy different is speed and appetite suppression: people lose weight fast and often eat far less protein while doing it, at the exact moment protein requirements per kilogram go up.
The consequences are not cosmetic. Lower muscle mass means lower resting energy expenditure, worse glucose disposal, poorer function with age, and an easier path to regaining fat after stopping.
What the drug combinations did
- Bimagrumab blocks activin type II receptors, the signaling node that suppresses muscle growth. In BELIEVE, adding it to semaglutide shifted the composition of the loss heavily toward fat while lean mass held.
- Trevogrumab is an anti-GDF8 (myostatin) antibody. In COURAGE, adding it to semaglutide preserved roughly half of the lean mass that semaglutide alone would have cost, and fat loss went up. An additional arm added garetosmab (anti-activin A).
- Both trials also reported numeric improvements in waist circumference, blood pressure, lipids and A1C across treatment groups.
- Neither trial is a longevity or performance study. These are obesity-quality-of-weight-loss trials in Phase 2.
What actually applies to you today
- Protein: roughly 1.2–1.6 g per kilogram of body weight per day during active loss, split across meals. Appetite suppression makes this a planning problem, not a willpower problem.
- Resistance training two to three times a week. It is the only intervention with consistent evidence for retaining muscle in a deficit, and it does not need to be complicated.
- Slow the taper. Titrating up faster than tolerated produces the sharpest deficits and the worst intake.
- Measure something other than weight: waist and hip circumference, grip strength, a repeatable lift, and body-composition scans if you have access.
- Be skeptical of gray-market 'myostatin inhibitor' peptides marketed off the back of these headlines. Follistatin-type products sold online are not the trial antibodies and have no human safety data.
How to track it in DoseRoutine
Body metrics and workout logging exist for exactly this pattern: log the GLP-1 dose and titration date, log weight and waist on a fixed cadence, log resistance sessions, and read them on the same timeline. When lean mass is the thing at risk, the useful signal is whether training volume and protein held while weight fell — not the number on the scale.
This is a summary of published research for general information. Investigational drugs are not available outside clinical trials, and research chemicals sold online are not the same products. Talk to a clinician who knows your history and labs before changing anything you take.
Frequently asked questions
How much muscle do you lose on GLP-1 medications?
Studies report that up to about 40% of the weight lost on GLP-1-based therapy can be lean mass, which includes skeletal muscle, connective tissue and water. The proportion is smaller when protein intake is adequate and resistance training is maintained.
What is bimagrumab?
Bimagrumab is an investigational monoclonal antibody that blocks activin type II receptors, releasing a brake on muscle growth. In the Phase 2 BELIEVE trial, combining it with semaglutide produced greater weight loss while preserving lean mass compared with semaglutide alone.
What is trevogrumab?
Trevogrumab is an investigational anti-GDF8 (anti-myostatin) antibody. In Regeneron's Phase 2 COURAGE trial, adding it to semaglutide prevented about half of the semaglutide-induced lean-mass loss while increasing fat-mass loss over 26 weeks.
Can I buy a myostatin inhibitor to protect muscle on a GLP-1?
Not legitimately. Bimagrumab and trevogrumab are investigational biologics available only in clinical trials. Peptides sold online as myostatin or follistatin products are unrelated research chemicals with no human efficacy or safety evidence for this use.
How much protein should I eat on a GLP-1?
Most clinical guidance during active weight loss lands around 1.2–1.6 g of protein per kilogram of body weight per day, spread across meals, combined with resistance training two to three times weekly. Discuss targets with your clinician if you have kidney disease.
Where to track this
- the best GLP-1 tracking apps compared for 2026 — How dose logging, titration history and side-effect notes differ across apps.
- how DoseRoutine handles GLP-1 protocols week to week — Weekly shot reminders, titration steps and missed-dose handling.
- tracking peptides, supplements and hormones in one place — Why a single timeline beats three separate apps when protocols overlap.
Related guides & tools
Matched to the compounds and mechanisms covered in this update.
Related updates
Other posts covering the same compounds, mechanisms and trial phases.
Keep reading
About the author
DoseRoutine Editorial Team — Maintainers of the DoseRoutine compound library and interaction rule set
The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine.
We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.
Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.
Sources & references
4 sources — primary literature, regulatory documents and company announcements, each linked to the original document. Last reviewed . How we select and review sources.
- AnnouncementHeymsfield SB, et al. Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial. Nat Med. 2026. View source on medicalxpress.com
- AnnouncementRegeneron Pharmaceuticals. Results from Phase 2 COURAGE trial demonstrating potential to improve quality of GLP-1 receptor agonist-induced weight loss by preserving lean mass. September 17, 2025. View source on investor.regeneron.com
- ReferencePennington Biomedical Research Center. Combination GLP-1 therapy shows fat mass loss while preserving lean mass in adults with obesity. March 5, 2026. View source on pbrc.edu
- Peer-reviewedWilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. View source on pubmed.ncbi.nlm.nih.gov